6 rezultatima
Randomized, open-label, parallel-group, multicenter, phase III trial with two arms, one with acalabrutinib (Arm A) and the other with the standard of care for the management of early Binet stage A patients "clinical observation (watch & wait)" (Arm B) in patients with untreated early stage CLL and
Inclusion criteria:
1. Males and females ≥ 20 years of age
2. ECOG performance status of 0-1
3. Histologically or cytologically verified non-squamous NSCLC
4. Stage IV disease, as defined by American Joint Committee on Cancer 7th edition staging, prior to first-line or second-line chemotherapy with
The immune system plays an important role in the fight against cancer. According to certain studies, Levels of cytokines secreted by the immune cells were found as predictors of prognosis and survival among cancer patients, as well as disease recurrence1. Pro-inflammatory cytokines, such as IL-6,
The Inflammatory Bowel Diseases (IBDs) are life-long conditions often diagnosed between 15 and 35 years of age that are increasing in frequency. In developed countries, IBD prevalence was about 100-220/100,000 in 2002. More recently the estimated prevalence of CD and UC in the USA are 201 and 238